| CAS No. | 1628730-49-3 |
|---|---|
| MDL No. | N/A |
| MF | C21H14F8N6O2 |
| MW | 534.40 |
| InChI Key | CYSJNTQNMDWAJV-UHFFFAOYSA-N |
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| 1 mg | 98% | $311 | In Stock | |
| 5 mg | 98% | $783 | In Stock | |
| 10 mg | 98% | $1131 | In Stock | |
| 25 mg | 98% | $1746 | In Stock | |
| 50 mg | 98% | $2260 | In Stock | |
| 100 mg | 98% | $3080 | In Stock | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Praliciguat is a 5-fluoro-2-(1H-pyrazol-3-yl)pyrimidine substituted with a 2-fluorobenzyl group at position 1, a 1,2-oxazol-3-yl group at position 5, and a [3,3,3-trifluoro-2-hydroxy-2-(trifluoromethyl)propyl]nitrilo group at position 4. It is a soluble guanylate cyclase stimulator under clinical development for heart failure with preserved ejection fraction. It functions as a soluble guanylate cyclase activator, anti-inflammatory agent, vasodilator, and antihypertensive. It belongs to isoxazoles, pyrazoles, organofluorine compounds, aminopyrimidines, tertiary alcohols, secondary amino compounds, and monofluorobenzenes.
| CAS No. | 1628730-49-3 |
|---|---|
| Product Name | Praliciguat |
